Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments

  • Technology appraisal guidance
  • TA954
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence